Biotech

All Articles

Actinogen's cortisol blocker neglects phase 2 depression research study

.Actinogen Medical's cortisol blocker has actually skipped the main endpoint of a stage 2 research i...

Bivictrix makes a decision going exclusive only technique to take ADC into medical clinic

.Antibody-drug conjugates (ADCs) have actually gone to the facility of many a billion-dollar biobuck...

TPG leadings up funds to $580M for investments all over life scientific researches

.Possession supervisor TPG, which has actually supported biotechs including Sionna Rehabs and also S...

Merck quits phase 3 TIGIT test in lung cancer cells for futility

.Merck &amp Co.'s TIGIT system has suffered an additional problem. Months after shuttering a period ...

After a challenging year, Exscientia folds in to Recursion

.After a year specified through pipe cuts, the shift of its own chief executive officer and cutbacks...

Cullinan, after $25M package, hands back bispecific to Harbour

.Cullinan Therapeutics was made an impression on sufficient with Port BioMed's bispecific immune rea...

A better check out Tough Biotech's Brutal 15

.Within this week's incident of "The Leading Pipe," we are actually diving right into Brutal Biotech...

Lilly deals with phase 2 failing of tau-targeting med

.The confetti is actually still soaring coming from Eli Lilly's event commemorating the approval of ...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our summary of considerable leadership hirings, shooting...

Lykos will ask FDA to rethink its own choice following being rejected of MDMA treatment for post-traumatic stress disorder

.Observing a bad showing for Lykos Therapeutics' MDMA candidate for post-traumatic stress disorder a...